Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop ...

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is the first in Delaware to offer a powerful new tool in ...

Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk of developing ...

Multiple myeloma is considered incurable, but a third of patients in a clinical trial have lived without detectable cancer for years, after facing certain death ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

In the front row, Dr. Bruno Paiva, with the team from the Multiple Myeloma Group at Cima and the Clínica Universidad de ...

ISB 2001, a first-in-class trispecific antibody developed by IGI, showed a 79% response rate in relapsed/refractory multiple ...

CellCentric has secured a Series C raise of $120million to advance its drug inobrodib, a first-in-class oral cancer drug to ...